LTRN Valuation

Lantern Pharma Inc

Add to Watchlist

Advanced Chart

3.460

-0.02(-0.575%)1D

LTRN Relative Valuation

LTRN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LTRN is overvalued; if below, it's undervalued.

Historical Valuation

Lantern Pharma Inc (LTRN) is now in the Fair zone, suggesting that its current forward PS ratio of 3.48 is considered Fairly compared with the five-year average of -4.51. The fair price of Lantern Pharma Inc (LTRN) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.59

Fair

-2.04

Trailing

Forward

0.00

EV/EBITDA

Lantern Pharma Inc. (LTRN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.73. The thresholds are as follows: Strongly Undervalued below -5.23, Undervalued between -5.23 and -2.98, Fairly Valued between 1.51 and -2.98, Overvalued between 1.51 and 3.76, and Strongly Overvalued above 3.76. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.10

EV/EBIT

Lantern Pharma Inc. (LTRN) has a current EV/EBIT of -1.10. The 5-year average EV/EBIT is -1.52. The thresholds are as follows: Strongly Undervalued below -7.29, Undervalued between -7.29 and -4.40, Fairly Valued between 1.37 and -4.40, Overvalued between 1.37 and 4.25, and Strongly Overvalued above 4.25. The current Forward EV/EBIT of -1.10 falls within the Historic Trend Line -Fairly Valued range.

3.46

Lantern Pharma Inc. (LTRN) has a current PS of 3.46. The 5-year average PS is 0.04. The thresholds are as follows: Strongly Undervalued below -0.74, Undervalued between -0.74 and -0.35, Fairly Valued between 0.43 and -0.35, Overvalued between 0.43 and 0.82, and Strongly Overvalued above 0.82. The current Forward PS of 3.46 falls within the Strongly Overvalued range.

0.00

P/OCF

Lantern Pharma Inc. (LTRN) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.14. The thresholds are as follows: Strongly Undervalued below -3.87, Undervalued between -3.87 and -1.86, Fairly Valued between 2.15 and -1.86, Overvalued between 2.15 and 4.15, and Strongly Overvalued above 4.15. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Lantern Pharma Inc. (LTRN) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.67. The thresholds are as follows: Strongly Undervalued below -12.30, Undervalued between -12.30 and -7.49, Fairly Valued between 2.14 and -7.49, Overvalued between 2.14 and 6.96, and Strongly Overvalued above 6.96. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Lantern Pharma Inc (LTRN) has a current Price-to-Book (P/B) ratio of 3.00. Compared to its 3-year average P/B ratio of 1.66 , the current P/B ratio is approximately 80.69% higher. Relative to its 5-year average P/B ratio of 1.82, the current P/B ratio is about 64.27% higher. Lantern Pharma Inc (LTRN) has a Forward Free Cash Flow (FCF) yield of approximately -0.43%. Compared to its 3-year average FCF yield of -33.33%, the current FCF yield is approximately -98.70% lower. Relative to its 5-year average FCF yield of -24.64% , the current FCF yield is about -98.24% lower.

2.98

P/B

Median3y

1.66

Median5y

1.82

-0.44

FCF Yield

Median3y

-33.33

Median5y

-24.64

Competitors Valuation Multiple

The average P/S ratio for LTRN's competitors is 2.64, providing a benchmark for relative valuation. Lantern Pharma Inc Corp (LTRN) exhibits a P/S ratio of 3.46, which is 30.90% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Rein Therapeutics Inc

Actinium Pharmaceuticals Inc

Onkure Therapeutics Inc

3.08

42.54M

Performance Decomposition

Market capitalization of LTRN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LTRN in the past 1 year is driven by Unknown.